Spain-based drug maker mAbxience is developing a biosimilar rituximab, RTXM83. Last week, researchers reported findings from a head-to-head study of the proposed biosimilar versus its reference product as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL).
Spain-based drug maker mAbxience is developing a biosimilar rituximab, RTXM83. Last week, researchers reported findings from a head-to-head study of the proposed biosimilar versus its reference product as a first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL).
The multicenter, double-blind, randomized study enrolled 272 newly diagnosed adult patients with DLBCL at 58 sites in 12 countries. Patients were randomized to receive either the reference or the biosimilar rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, and patients were followed for up to 9 months after their last study dose.
The primary efficacy endpoint was to compare overall response rate (ORR) in each treatment arm after cycle 6 or 30 days after the last study dose. Pharmacokinetics (PK), pharmacodynamics (PD), event-free survival (EFS), safety, and immunogenicity were secondary endpoints that were evaluated during treatment and follow-up.
In total, 85% of patients completed all 6 cycles of the study treatment. Exposure to rituximab was similar in the biosimilar and reference arms. In the 239 patients who comprised the intent-to-treat population, after 6 cycles of treatment, the investigators observed a 0.7% difference in ORR in favor of the biosimilar versus the reference (83.6% vs 82.9%), though this difference was not statistically significant. The lower bound of the 95% confidence interval of the difference was —8.77%, which was above the prespecified noninferiority margin of –13%.
Median EFS in the biosimilar and reference arms was similar (12.5 months vs 8.6 months, respectively; P =.4613). PK and PD measurements were also similar in both arms.
The proportion of patients with at least one treatment-emergent adverse event (AE) or serious AE was the same in each arm (96%), and the nature and frequency of AEs were in line with the known profile of rituximab in combination with CHOP. The most frequently reported AEs included hematologic toxicities, infections, and infusion-related reactions.
There was a low incidence of anti-drug antibodies (ADAs) in both treatment arms; 2.3% of patients in the biosimilar arm and 3.2% of those in the reference arm developed new ADAs.
According to the authors, this study—believed to be the first randomized, double-blind study of a biosimilar in patients with DLBCL—demonstrated the noninferiority of the biosimilar to the reference in terms of efficacy and supports the similarity of the 2 rituximab products.
Reference
Candelaria M, González DE, Delamain MT, et al. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study [published online July 4, 2019]. Leuk Lymphoma. doi: 10.1080/10428194.2019.1633632.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
New Year, New Hurdles: What's in Store for Biosimilars in 2023
December 18th 2022On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
November 15th 2023In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.